Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 12Gastrointestinal 8Gynecologic 4Genitourinary 4Head & Neck 3Breast 3Dermatologic 2Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1NET 1Lymphoid 1Endocrine 1

Conditions

Carcinoma, Neuroendocrine 5Neoplasms 3Vipoma 2Somatostatinoma 2Neuroendocrine Tumors 2Insulinoma 2Glucagonoma 2Gastrinoma 2Carcinoma, Islet Cell 2Adenoma, Islet Cell 2Thyroid Carcinoma, Anaplastic 1Lung Neoplasms 1Head and Neck Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Radiosurgery 4Paclitaxel 4atezolizumab 3Nivolumab 3selpercatinib 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Irinotecan 2Carboplatin 2vandetanib 1taxane 1sargramostim 1romidepsin 1repotrectinib 1pralsetinib 1pentetreotide 1niraparib 1liposomal doxorubicin 1dostarlimab 1aldesleukin 1Vinorelbine 1Topotecan 1Thalidomide 1Temozolomide 1Specimen Handling 1Rose Bengal 1Radiation 1RRx-001 1Quality of Life 1Proton Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Fluorouracil × Endocrine × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡